In vivo, fisetin administration attenuated joint degeneration in mice with induced osteoarthritis, as well as reducing subchondral bone plaque thickness and alleviating synovitis, confirming its efficacy in modulating disease progression through SIRT1 [60]. This evidence concerns the gene SIRT1 and osteoarthritis.